Nurse-led program for long-acting HIV prevention shots
Part of Immune system & allergy, Infections clinical trials.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting medical care at one of our clinics.
- You are 18 or older.
- You have a negative HIV test and want PrEP to prevent HIV.
- You did not have a high-risk HIV exposure or symptoms in the last month.
- You can keep your appointments and have a reliable way to be contacted (like a phone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
This study is for people who are already taking or about to start long-acting injectable HIV PrEP (shots instead of daily pills). The goal is to learn about your experiences and preferences with this type of PrEP. It takes place in Louisville, Kentucky.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.